CTOs on the Move

Microbion

www.microbioncorp.com

 
Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Microbion raised $25M on 01/06/2017
Microbion raised $17.1M on 05/28/2020

Similar Companies

BlueWillow Biologics

NanoBio® is a division of BlueWillow Biologics, Inc., a privately-held biopharmaceutical company focused on developing intranasal vaccines and topical anti-infective therapies based on its patented nanotechnology platform.

Ockham Development Group

Ockham Development Group is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eccrine Systems

Eccrine Systems, Inc., is focused on the development of non-invasive disposable electronic patches that accurately measure and transmit real-time data about human sweat. Applications for our technology and IP span market opportunities within medicine, industry, and sports. We seek to establish exclusive collaborations with downstream partners who understand the opportunity for embedding and deploying our technology in their market-specific applications. Our role in these collaborations is the modular development and prototyping of desired sweat sensor features and capabilities. Our partners embed our technology in their commercial applications and translate data about sweat and other biometrics into high value products for their customers.

Bamboo Therapeutics

Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.

Epitopix

Epitopix is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.